Itolizumab Not To Be Included In Clinical Managment Of COVID-19

The National Task Force for COVID-19 has decided to not include Biocon's Itolizumab in the clinical management protocols for COVID-19 due to lack of evidence, PTI reported.

Although approved for "restricted emergency use" by the Drugs Controller General of India, the monoclonal antibody used to treat psoriasis and produced by Kiran Mazumdar Shaw's Biocon, did not find favour with the task force. Officials told PTI that they feel there is not enough evidence to support that the drug reduces cytokine storms in patients.